NeoGenomics is pleased to announce a speaker program titled ‘Minimal Residual Disease in Colorectal Cancer.’
Learn from industry-leading GI oncology experts in this educational, three-part virtual webinar series on minimal residual disease (MRD) in colorectal cancer (CRC), followed by an open Q&A session. Attendees will learn how these experts use ctDNA and MRD assessment to guide treatment decisions and identify patients at risk for recurrence following curative intent therapy.
Each session will be led by a leading CRC medical oncologist. We invite you to learn about each of them below.
Links to recordings:
- Day One with Scott Kopetz, MD, PhD, FACP
- Day Two with Pashtoon Kasi, MD, MS
- Day Three with Bassel El-Rayes, MD
Scott Kopetz, MD, PhD, FACP Oncologist; Deputy Chair, GI Medical Oncology; Del and Dennis McCarthy Distinguished Professor; NCI Colon Task Force Chair @MD Anderson Cancer Center Dr. Kopetz joined MD Anderson Cancer Center in 2006 and serves as Professor and Deputy Chair, GI Medical Oncology. Dr. Kopetz is board-certified in internal medicine and medical oncology. He has authored 350+ peer-reviewed articles in journals such as NEJM, J. Clin. Oncol., Lancet, Lancet Oncology, JAMA, Cancer Discovery, and Nature Medicine. He is the principal investigator of several Phase 1, 2, and 3 clinical trials, including trials for patients with BRAF mutated CRC that led to new standards of care. Dr. Kopetz graduated from Vanderbilt University with a bachelors in biomedical engineering/electrical engineering. He received his medical degree from Johns Hopkins School of Medicine. Dr. Kopetz completed his internal medicine residency at Duke University, his medical oncology fellowship at MD Anderson Cancer Center, and obtained a PhD at University of Texas in patient oriented biological research/cancer biology with his thesis focused on mechanisms of chemotherapy resistance in CRC.
Pashtoon Kasi, MD, MS Director of Colorectal Cancer Research; Precision Medicine Director for LBx Research; Asst. Attending Physician; Asst. Professor · Weill Cornell Medical College/New York-Presbyterian Hospital Dr. Pashtoon Kasi, MD, MS is an oncologist and researcher at Weill Cornell Medicine and New York-Presbyterian Hospital. He focuses on treating patients with gastrointestinal (GI) cancers and the treatment of patients with novel drugs/early-phase clinical trials. At Weill Cornell Medicine, Dr. Kasi additionally serves as the Director for Colorectal Cancer Research, as well as Precision Medicine Director for Liquid Biopsy Research at the Englander Institute of Precision Medicine.
Bassel El-Rayes, MD Director of the Division of Hematology and Oncology and the Deputy Cancer Center Director @O’Neal Comprehensive Cancer Center of the University of Alabama at Birmingham Bassel F. El-Rayes, M.D. is the Director of the Division of Hematology and Oncology and the Deputy Cancer Center Director of the O’Neal Comprehensive Cancer Center of the University of Alabama at Birmingham. Dr. El-Rayes earned his bachelors and doctorate from the American University of Beirut. He completed his residency in internal medicine and fellowship in hematology and medical oncology at Wayne State University.
Dr. El-Rayes’ clinical interests include GI malignancies specifically pancreatobiliary and neuroendocrine cancers. He is principle investigator on multiple investigator-initiated trials. He has peer-reviewed funding including from National Cancer Institute. He has served on the gastrointestinal committee for SWOG and RTOG. He currently serves on the Alliance Oncology. He also serves as Co-chair of Hoosier Cancer Research Network's GI Clinical Trials Group. Dr. El-Rayes has published over 250 peer reviewed articles in elite journals including JCO and Cancer Research.